RxDoctor Payments Data

Dina Doolin, DO

Family Medicine · New Smyrna Beach, FLNPI 1356446223

Payments from drug & device makers

$8,045in general payments, 2019–2025

Across 403 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Novo Nordisk$1K
  • Pfizer$644
  • Phathom Pharmaceuticals, Inc.$426
  • Lilly USA, LLC$360
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$8,007100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,045 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$250,066
Medicare patients
534
Services billed
4,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$148,088
OzempicSemaglutide52$56,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$41,461
MounjaroTirzepatide29$36,525
JardianceEmpagliflozin13$23,039
XareltoRivaroxaban15$22,209
JanuviaSitagliptin Phosphate13$21,468
LinzessLinaclotide19$17,928
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen629$10,431
Albuterol Sulfate HfaAlbuterol Sulfate148$5,831
Levothyroxine Sodium460$4,300
Losartan Potassium382$4,065
Rosuvastatin Calcium308$3,904
Novolog FlexpenInsulin Aspart14$3,697
Atorvastatin Calcium356$3,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$644$148,088122 claims
Novo NordiskOzempic$1,148$56,73252 claims
GSKTrelegy Ellipta$109$41,46142 claims
Lilly USA, LLCMounjaro$360$36,52529 claims
Boehringer IngelheimJardiance$120$23,03913 claims
Johnson & JohnsonXarelto$16$22,20915 claims
AbbVieLinzess, Synthroid$1,361$19,89151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in New Smyrna Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →